Loading…
Lobbying Spend
—
Filings
17
Firms Hired
1
Active Period
2012–2016
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Safeguarding America's Pharmaceuticals Act of 2013
2013 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Advocated for provisions recognizing the role of drug repackagers who do not hold title to products in congressional proposals regarding regulating the pharmaceutical supply chain; Advocated that company should not be classified as "contract pharmacy" under 340B program; S.959, the Pharmaceutical Quality & Security Accountability Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1919
Pharmaceutical Quality, Security, and Accountability Act
2013 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Advocated for provisions recognizing the role of drug repackagers who do not hold title to products in congressional proposals regarding regulating the pharmaceutical supply chain; Advocated that company should not be classified as "contract pharmacy" under 340B program; S.959, the Pharmaceutical Quality & Security Accountability Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013.
Client expense: — · Firm income: $10,000
Matched citations: S.959
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012. Advocated for provisions recognizing the role of drug repackagers and against provisions to make certain hydrocodone products schedule 2 controlled substances.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012. Advocated for provisions recognizing the role of drug repackagers and against provisions to make certain hydrocodone products schedule 2 controlled substances.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012. Advocated for provisions recognizing the role of drug repackagers and against provisions to make certain hydrocodone products schedule 2 controlled substances.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012. Advocated for provisions recognizing the role of drug repackagers and against provisions to make certain hydrocodone products schedule 2 controlled substances.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012.
Client expense: — · Firm income: —
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012.
Client expense: — · Firm income: —
Matched citations: H.R. 5651
Source: Senate LDA